Adrenal insufficiency in patients taking benralizumab as corticosteroid sparing therapy
- PMID: 34762848
- DOI: 10.1016/S2213-2600(21)00487-2
Adrenal insufficiency in patients taking benralizumab as corticosteroid sparing therapy
Conflict of interest statement
BL reports non-financial support (equipment) from GSK; grants, personal fees (consulting, talks, and advisory board), and other support (attending American Thoracic Society and European Respiratory Society [ERS]) from AstraZeneca; grants, personal fees (consulting, talks, advisory board), and other support (attending ERS) from Teva; personal fees (consulting, talks and advisory board) from Circassia in relation to the submitted work; personal fees (consulting) from Sanofi, Lupin, Glenmark, Vectura, Dr Reddy, and Sandoz; grants, personal fees (consulting, talks, advisory board), other support (attending British Thoracic Society) from Boehringer Ingelheim; grants and personal fees (advisory board and talks) from Mylan outside of the submitted work. BL's son is an employee of AstraZeneca. RM and RC declare no competing interests.
Comment on
-
Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study.Lancet Respir Med. 2022 Jan;10(1):47-58. doi: 10.1016/S2213-2600(21)00352-0. Epub 2021 Oct 4. Lancet Respir Med. 2022. PMID: 34619104
-
Adrenal insufficiency in patients taking benralizumab as corticosteroid sparing therapy - Authors' reply.Lancet Respir Med. 2022 Jan;10(1):e8. doi: 10.1016/S2213-2600(21)00489-6. Epub 2021 Nov 8. Lancet Respir Med. 2022. PMID: 34762847 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
